<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02053883</url>
  </required_header>
  <id_info>
    <org_study_id>BA-210-201</org_study_id>
    <nct_id>NCT02053883</nct_id>
  </id_info>
  <brief_title>Cethrin in Acute Cervical Spinal Cord Injury</brief_title>
  <official_title>A Phase II/III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Cethrin in Subjects With Acute Cervical Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioAxone BioSciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioAxone BioSciences, Inc.</source>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled Phase IIb/III study
      designed to evaluate the efficacy and safety of Cethrin as a treatment for acute cervical
      spinal cord injury. During the trial, high and low doses of Cethrin will be compared with
      placebo.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Compound recently partnered with another company for continued development.
  </why_stopped>
  <start_date>July 2015</start_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>American Spinal Injury Association (ASIA) Upper Extremity Motor Score Recovery</measure>
    <time_frame>Baseline to 6 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ASIA Total Motor Score Recovery</measure>
    <time_frame>Baseline to 6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASIA Impairment Scale (AIS) Grade Recovery</measure>
    <time_frame>Baseline to 6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor Neurological Level Recovery</measure>
    <time_frame>Baseline to 6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASIA Sensory Score Recovery</measure>
    <time_frame>Baseline to 6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spinal Cord Independence Measure (SCIM) III (Total Score, Self-Care Subscore)</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graded Redefined Assessment of Strength, Sensibility and Prehension (GRASSP)</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>0-6 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Fibrin sealant only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cethrin (BA-210) - Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose of Cethrin in a fibrin sealant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cethrin (BA-210) - High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose of Cethrin in a fibrin sealant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cethrin (BA-210)</intervention_name>
    <description>High or low doses of Cethrin administered extradurally in a fibrin sealant during spinal decompression/stabilization surgery.</description>
    <arm_group_label>Cethrin (BA-210) - Low Dose</arm_group_label>
    <arm_group_label>Cethrin (BA-210) - High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Fibrin sealant alone administered extradurally during spinal decompression/stabilization surgery.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females, ages 18-62, inclusive

          -  Acute cervical spinal cord injury at a neurological level of C4-C6

          -  AIS Grade A or B

          -  Scheduled to undergo decompression/stabilization surgery within five days of injury

          -  Written or verbal consent from patient or legally authorized representative that
             patient is able and willing to comply with the study protocol, including follow-up
             visits

        Exclusion Criteria:

          -  Participation in any other clinical trial for acute SCI, including previous Cethrin
             trial

          -  Inability to receive study medication within five days of injury

          -  Acute SCI from gunshot or penetrating/stab wound; peripheral nerve injury; brachial
             plexus injury; complete spinal cord transection; or multifocal SCI

          -  Significant hemorrhage on MRI/CT scan

          -  Females who are breastfeeding or have a positive serum pregnancy test

          -  Body mass index (BMI) of â‰¥ 35 kg/m2 at screening

          -  History of an adverse reaction to a fibrin sealant or its human or bovine components

          -  Use of intravenous heparin in previous 48 hours, aspirin-containing products in
             previous 24 hours, thrombolytics in previous 12 hours

          -  Hemophilia or other bleeding abnormality (platelet level lower than 100 X 109/L,
             activated partial thromboplastin time or international normalized ratio higher than
             the upper limit of normal, or baseline hematocrit lower than 0.25)

          -  Unconsciousness or other impairment that precludes reliable ASIA examination

          -  Known immunodeficiency, including human immunodeficiency virus, or use of
             immunosuppressive or cancer chemotherapeutic drugs

          -  Clinically significant pre-existing neurological, cardiac, respiratory, hepatic, or
             renal disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>62 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2014</study_first_submitted>
  <study_first_submitted_qc>February 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2014</study_first_posted>
  <last_update_submitted>November 25, 2014</last_update_submitted>
  <last_update_submitted_qc>November 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SCI</keyword>
  <keyword>spinal cord injury</keyword>
  <keyword>biologic drug</keyword>
  <keyword>rho</keyword>
  <keyword>paralysis</keyword>
  <keyword>paraplegia</keyword>
  <keyword>tetraplegia</keyword>
  <keyword>quadriplegia</keyword>
  <keyword>trauma</keyword>
  <keyword>central nervous system</keyword>
  <keyword>fibrin sealant</keyword>
  <keyword>neurosurgery</keyword>
  <keyword>cervical</keyword>
  <keyword>regeneration</keyword>
  <keyword>neurotrauma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrin Tissue Adhesive</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

